JP2022510304A5 - - Google Patents
Info
- Publication number
- JP2022510304A5 JP2022510304A5 JP2021531035A JP2021531035A JP2022510304A5 JP 2022510304 A5 JP2022510304 A5 JP 2022510304A5 JP 2021531035 A JP2021531035 A JP 2021531035A JP 2021531035 A JP2021531035 A JP 2021531035A JP 2022510304 A5 JP2022510304 A5 JP 2022510304A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- solid solution
- capsule formulation
- nonionic surfactant
- solution capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773848P | 2018-11-30 | 2018-11-30 | |
| US62/773,848 | 2018-11-30 | ||
| PCT/US2019/063547 WO2020112961A1 (en) | 2018-11-30 | 2019-11-27 | Capsule formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510304A JP2022510304A (ja) | 2022-01-26 |
| JP2022510304A5 true JP2022510304A5 (cg-RX-API-DMAC7.html) | 2023-03-15 |
| JP7342124B2 JP7342124B2 (ja) | 2023-09-11 |
Family
ID=70849818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531035A Active JP7342124B2 (ja) | 2018-11-30 | 2019-11-27 | カプセル製剤 |
Country Status (31)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164403A (zh) | 2018-11-30 | 2021-07-23 | 凯莫森特里克斯股份有限公司 | 胶囊制剂 |
| KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| CA3192880A1 (en) * | 2020-10-28 | 2022-05-05 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| CN116635075A (zh) * | 2020-12-21 | 2023-08-22 | 坎莫森特里克斯公司 | 使用c5a抑制剂治疗c3肾小球病 |
| JP2025516701A (ja) * | 2022-05-19 | 2025-05-30 | ダウ グローバル テクノロジーズ エルエルシー | Bcsクラスiiの薬物の改良された可溶化のためのpegベースのインターポリマー錯体の使用 |
| US20250164505A1 (en) * | 2023-11-20 | 2025-05-22 | Qatar Foundation For Education, Science And Community Development | Detection of extracellular vesicle biomarkers for the diagnosis of autism spectrum disorder |
| WO2025203055A1 (en) * | 2024-03-26 | 2025-10-02 | Council Of Scientific And Industrial Research | Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038681A1 (es) | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| AU2005309808A1 (en) * | 2004-11-24 | 2006-06-01 | Merck & Co., Inc. | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
| DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
| MX363066B (es) * | 2007-05-29 | 2019-03-07 | Intrexon Corp | Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona. |
| JP5819730B2 (ja) | 2008-12-22 | 2015-11-24 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト |
| US20110312973A1 (en) | 2010-03-10 | 2011-12-22 | Bernd Liepold | Solid compositions |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| EP2659090B1 (en) | 2010-12-27 | 2017-08-23 | Seven Generations Energy Ltd. | Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources |
| CN106102716A (zh) | 2014-02-05 | 2016-11-09 | 斯洛文尼亚莱柯制药股份有限公司 | 雄激素受体拮抗剂的固体药物组合物 |
| JP6898229B6 (ja) | 2014-09-29 | 2021-07-28 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト製造における方法及び中間体 |
| SG11201805828YA (en) | 2016-01-14 | 2018-08-30 | Chemocentryx Inc | Method of treating c3 glomerulopathy |
| SG11201808625QA (en) | 2016-04-04 | 2018-10-30 | Chemocentryx Inc | SOLUBLE C5aR ANTAGONISTS |
| DK3411400T3 (da) | 2017-04-03 | 2021-10-11 | Inflarx Gmbh | Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet |
| CN111741754A (zh) | 2017-10-30 | 2020-10-02 | 凯莫森特里克斯股份有限公司 | 作为免疫调节剂的氘代化合物 |
| KR20200109297A (ko) | 2017-10-31 | 2020-09-22 | 케모센트릭스, 인크. | 소변 sCD163의 C5aR 억제제 감소 |
| JP2021527062A (ja) | 2018-06-07 | 2021-10-11 | ケモセントリックス,インコーポレイティド | ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果 |
| CN113164403A (zh) | 2018-11-30 | 2021-07-23 | 凯莫森特里克斯股份有限公司 | 胶囊制剂 |
-
2019
- 2019-11-27 CN CN201980079276.4A patent/CN113164403A/zh active Pending
- 2019-11-27 SI SI201930868T patent/SI4233850T1/sl unknown
- 2019-11-27 SM SM20240521T patent/SMT202400521T1/it unknown
- 2019-11-27 SI SI201930524T patent/SI3886820T1/sl unknown
- 2019-11-27 MD MDE20210972T patent/MD3886820T2/ro unknown
- 2019-11-27 HR HRP20241735TT patent/HRP20241735T1/hr unknown
- 2019-11-27 LT LTEP23160271.5T patent/LT4233850T/lt unknown
- 2019-11-27 EP EP19889873.6A patent/EP3886820B8/en active Active
- 2019-11-27 WO PCT/US2019/063547 patent/WO2020112961A1/en not_active Ceased
- 2019-11-27 KR KR1020217019883A patent/KR102586747B1/ko active Active
- 2019-11-27 EP EP24196793.4A patent/EP4487915A3/en active Pending
- 2019-11-27 ES ES19889873T patent/ES2943492T3/es active Active
- 2019-11-27 RS RS20241401A patent/RS66362B1/sr unknown
- 2019-11-27 CA CA3120999A patent/CA3120999C/en active Active
- 2019-11-27 DK DK23160271.5T patent/DK4233850T3/da active
- 2019-11-27 LT LTEPPCT/US2019/063547T patent/LT3886820T/lt unknown
- 2019-11-27 MD MDE20231131T patent/MD4233850T2/ro unknown
- 2019-11-27 JP JP2021531035A patent/JP7342124B2/ja active Active
- 2019-11-27 BR BR112021010285-0A patent/BR112021010285A2/pt not_active Application Discontinuation
- 2019-11-27 DK DK19889873.6T patent/DK3886820T3/da active
- 2019-11-27 EP EP23160271.5A patent/EP4233850B1/en active Active
- 2019-11-27 PL PL23160271.5T patent/PL4233850T3/pl unknown
- 2019-11-27 MA MA54318A patent/MA54318B1/fr unknown
- 2019-11-27 PT PT231602715T patent/PT4233850T/pt unknown
- 2019-11-27 HU HUE23160271A patent/HUE069633T2/hu unknown
- 2019-11-27 FI FIEP19889873.6T patent/FI3886820T3/fi active
- 2019-11-27 NZ NZ776554A patent/NZ776554A/en unknown
- 2019-11-27 HR HRP20230551TT patent/HRP20230551T1/hr unknown
- 2019-11-27 HU HUE19889873A patent/HUE062551T2/hu unknown
- 2019-11-27 ES ES23160271T patent/ES2998858T3/es active Active
- 2019-11-27 IL IL283450A patent/IL283450B2/en unknown
- 2019-11-27 RS RS20230433A patent/RS64250B1/sr unknown
- 2019-11-27 SM SM20230153T patent/SMT202300153T1/it unknown
- 2019-11-27 AU AU2019389031A patent/AU2019389031B2/en active Active
- 2019-11-27 SG SG11202105572UA patent/SG11202105572UA/en unknown
- 2019-11-27 MX MX2021006242A patent/MX2021006242A/es unknown
- 2019-11-27 PL PL19889873.6T patent/PL3886820T3/pl unknown
- 2019-11-27 US US16/697,523 patent/US20200170957A1/en not_active Abandoned
- 2019-11-27 MA MA62992A patent/MA62992B1/fr unknown
- 2019-11-27 PT PT198898736T patent/PT3886820T/pt unknown
- 2019-11-27 FI FIEP23160271.5T patent/FI4233850T3/fi active
- 2019-11-29 AR ARP190103505A patent/AR117219A1/es unknown
- 2019-11-29 TW TW108143799A patent/TWI827745B/zh active
-
2021
- 2021-05-27 CL CL2021001389A patent/CL2021001389A1/es unknown
- 2021-06-03 ZA ZA2021/03820A patent/ZA202103820B/en unknown
- 2021-12-08 US US17/545,878 patent/US11951214B2/en active Active
-
2023
- 2023-07-03 CY CY20231100309T patent/CY1126079T1/el unknown
-
2024
- 2024-02-09 US US18/437,368 patent/US20240299306A1/en not_active Abandoned
-
2025
- 2025-08-28 US US19/313,405 patent/US20250375385A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283450B1 (en) | Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses | |
| JP7577069B2 (ja) | 嚢胞性線維症膜貫通コンダクタンス制御因子調節剤 | |
| JP5684192B2 (ja) | トリアゾロ[4,5−d]ピリミジン化合物の新規な結晶形及び非晶形 | |
| JP2001520645A (ja) | 新規な化合物 | |
| US9796685B2 (en) | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide | |
| CA3068609A1 (en) | Compositions and methods for treatment of cystic fibrosis | |
| JPH0696524B2 (ja) | バルプロ酸をベ−スとした新規薬剤組成物及びその製法 | |
| CN105338982B (zh) | 固体药用组合物 | |
| JP2014525463A5 (cg-RX-API-DMAC7.html) | ||
| JP2005511538A5 (cg-RX-API-DMAC7.html) | ||
| KR20180086497A (ko) | sGC 자극제를 포함하는 고체 분산물 | |
| TW200815360A (en) | Novel compounds | |
| JP2005516009A (ja) | 重水素化された置換ピラゾリル−ベンゼンスルホンアミド並びにこれを含有する医薬品 | |
| JP2023501789A5 (cg-RX-API-DMAC7.html) | ||
| TW214552B (cg-RX-API-DMAC7.html) | ||
| CN114206842A (zh) | 盐 | |
| TW201720444A (zh) | 含有2-{4-[n-(5,6-二苯基吡 -2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物 | |
| TW201304779A (zh) | 醫藥組合物 | |
| TW201006819A (en) | Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion | |
| TWI358407B (en) | Crystalline base of escitalopram and orodispersibl | |
| RU2021118878A (ru) | Лекарственные формы в виде капсул | |
| CN113330007A (zh) | 尼拉帕利游离碱的晶体形式 | |
| CN111263754A (zh) | 结晶 | |
| JP2003510267A (ja) | 医薬担体処方 | |
| WO2021137835A1 (en) | Penicillin derivatives and method for their synthesis |